Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2005
03/10/2005US20050053594 RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK
03/10/2005US20050053592 Genes in cancer and polynucleotides with codes for polypeptides with amino acid sequences
03/10/2005US20050053589 Interleukins (IL13); site-directed mutagenesis; for treatment of cancer; kits
03/10/2005US20050053583 Method of inhibiting prion protein
03/10/2005US20050053581 Which effect p53 binding/inactivation; enhances efficacy of such viruses for treating cancer; liposomes
03/10/2005US20050053580 Antisense oligonucleotides, stabilized ribozymes, aptamers, mirror aptamers, chimeric RNA/DNA oligonucleotides, naked plasmid-DNA or liposomally encapsulated DNA which code for androgen receptor and/or the testosterone 5 alpha-reductase; sebocytes; keratinocytes
03/10/2005US20050053579 Conjugates of cytokines, chemokines, and interferons; genetic vaccines; for reducing tumor growth
03/10/2005US20050053575 Antigenic product displaying multiple copies of an epitope of a deposit-forming polypeptide involved in plaque-forming diseases and methods of using same
03/10/2005US20050053548 Degrading collagen within an atherosclerotic plaque in a chronically occluded animal tube or cavity by administering proteolytic enzyme; angioplasty
03/10/2005CA2548483A1 Induction of antiviral neutralizing antibodies in humans and animals
03/10/2005CA2543078A1 Diagnosis and treatment of micobacterial infections
03/10/2005CA2538507A1 Acid soluble proteins from micellar casein
03/10/2005CA2537238A1 Delivery of therapeutic compounds to the brain and other tissues
03/10/2005CA2537184A1 Gene therapy for skin disorders using needleless syringes
03/10/2005CA2537179A1 Anti-angiogenic peptides from the n-terminus of endostatin
03/10/2005CA2537137A1 Use of modified cyclosporins for the treatment of hcv disorders
03/10/2005CA2537113A1 Modified protease inhibitors
03/10/2005CA2536968A1 Collagen hydrolysate
03/10/2005CA2536912A1 Combination therapy for the treatment of ocular neovascular disorders
03/10/2005CA2536906A1 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
03/10/2005CA2536873A1 Poly-pegylated protease inhibitors
03/10/2005CA2536868A1 Enhancing the circulating half-life of interleukin-2 proteins
03/10/2005CA2536570A1 Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
03/10/2005CA2536466A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
03/10/2005CA2536458A1 Composition comprising a pulmonary surfactant and a pde2 inhibitor
03/10/2005CA2536453A1 Use of surfactant preparations for the treatment of surgical adhesions
03/10/2005CA2536205A1 Human obesity susceptibility gene and uses thereof
03/10/2005CA2535856A1 Fusion polypeptides, and use thereof in antivascular tumor therapy
03/10/2005CA2535522A1 Fsh glycosylation mutant
03/10/2005CA2529027A1 D-amino acid peptides
03/10/2005CA2525374A1 Delivery of compounds with rehydrated blood cells
03/10/2005CA2510677A1 Amino acid derived prodrugs of propofol, compositions and uses thereof
03/09/2005EP1512697A1 TNF Receptor action modulation
03/09/2005EP1512695A1 Hypoallergenic polypeptides based on fish parvalbumin
03/09/2005EP1512692A2 Novel inhibitors of prenylated pyrophosphate consuming enzymes
03/09/2005EP1512688A1 Use of K-252a derivatives for the treatment of Parkinson's disease
03/09/2005EP1512415A1 Decoy composition for treating and preventing inflammatory disease
03/09/2005EP1512411A1 Treatment of neuromuscular disorders and conditions with different botulinum serotype
03/09/2005EP1512410A1 Use of a composition for treating organ tissue injury caused by reperfusion of blood flow following a period of ischemia
03/09/2005EP1512328A1 Soluble soy protein with superior functional properties
03/09/2005EP1512110A2 Screening process
03/09/2005EP1512016A1 Screening method and anti-tumor drug candidate obtained therefrom
03/09/2005EP1512014A2 Methods for the identification of all-antigens and their use for cancer therapy and transplantation
03/09/2005EP1512008A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
03/09/2005EP1512007A2 32235, a human aminotransferase family member and uses therefor
03/09/2005EP1511853A2 Regulation of novel human asparagine-hydroxylases
03/09/2005EP1511846A1 Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence
03/09/2005EP1511844A2 Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules
03/09/2005EP1511790A1 Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications
03/09/2005EP1511772A2 Method for obtaining anti-idiotype antibodies
03/09/2005EP1511770A2 Immunoadhesin comprising a glycoprotein vi domain
03/09/2005EP1511768A1 Immunogenic compositions
03/09/2005EP1511765A1 Par-2-activating peptide derivative and pharmaceutical composition using the same
03/09/2005EP1511764A2 PEPTIDES AND PEPTIDOMIMETICS USEFUL FOR INHIBITING THE ACTIVITY OF PROSTAGLANDIN F sb 2a /sb RECEPTOR
03/09/2005EP1511763A2 Intracellular delivery of biological effectors
03/09/2005EP1511759A1 Modulators and inhibitors of fibroblast growth factor receptor 5-polypeptides and gene expression thereof.
03/09/2005EP1511537A2 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
03/09/2005EP1511520A2 Compositions and methods for the use of bcl-2 transfected neurons
03/09/2005EP1511519A1 Modified byrodin 1 with reduced immunogenicity
03/09/2005EP1511514A1 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
03/09/2005EP1511512A1 Novel uses of parapoxvirus preparations
03/09/2005EP1511511A2 Use of il-19, il-22 and il-24 to treat hematopoietic disorders
03/09/2005EP1511510A1 Use of uk114 in the treatment of leishmaniasis
03/09/2005EP1511509A1 Compositions and methods for treating diabetes
03/09/2005EP1511508A2 Method of treating dyslipidemic disorders
03/09/2005EP1511507A1 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
03/09/2005EP1511506A1 Compositions and methods for preventing, treating and diagnosing diabetes
03/09/2005EP1511505A2 Novel therapies and methods of screening for therapeutic compounds
03/09/2005EP1511502A2 Probiotic therapies using lactobacillus reuteri
03/09/2005EP1511491A1 Derivatives of azepine and thiazepan as interleukin converting enzyme inhibitors
03/09/2005EP1511480A2 Inhibitors of glycoprotein vi
03/09/2005EP1511474A1 A method of treatment
03/09/2005EP1511471A1 Colloidal suspension of submicronic particles for delivering active principles and method for preparing same
03/09/2005EP1511466A1 Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
03/09/2005EP1511397A1 Dietary method for modulatng glucose metabolism and associated conditions and increasing longevity
03/09/2005EP1511393A1 A method of improving the growth performance of an animal
03/09/2005EP1511378A2 Antifungal parenteral products
03/09/2005EP1448053A4 Proliferation and differentiation of stem cells using extracellular matrix and other molecules
03/09/2005EP1432407B1 Lisinopril compositions having large-particle dcpd
03/09/2005EP1429798A4 Optimal compositions and methods thereof for treating hcv infections
03/09/2005EP1392354B1 Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic wounds
03/09/2005EP1296554A4 Prevention and treatment of mycoplasma-associated diseases
03/09/2005EP1237916B1 Ing2, an iaps associated cell cycle protein, compositions and methods of use
03/09/2005EP1159423B1 Uses of transgenic animals containing a type x collagen mutant
03/09/2005EP1126849B1 Heterocyclic potassium channel inhibitors
03/09/2005EP1108026B1 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
03/09/2005EP0944645B1 INHIBITORS OF INTERLEUKIN-1beta CONVERTING ENZYME
03/09/2005EP0938556B1 Gamma-heregulin
03/09/2005EP0932613B1 Blocking expression of virulence factors in s. aureus
03/09/2005EP0845943B1 Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
03/09/2005EP0842273B1 Receptor ligand vegf-c
03/09/2005EP0801679B1 Monoclonal antibodies which promote central nervous system remyelination
03/09/2005EP0784481B1 Wound healing formulations containing human plasma fibronectin
03/09/2005EP0779076B1 Peptide, a method of obtaining it and a pharmaceutical compound based on it
03/09/2005EP0756005B1 Gene coding for adseverin
03/09/2005EP0673241B1 Use of a free radical quenching liposomal composition for the manufacture of a medicament for the treatment of inflammatory conditions
03/09/2005CN1592794A Cell culture system for synthesis of infectious hepatitis C virus
03/09/2005CN1592791A Phytases, nucleic acids encoding them and methods for making and using them
03/09/2005CN1592755A Anti-angiogenic peptides
03/09/2005CN1592753A Methods for preparing purified daptomycin
1 ... 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 ... 3163